Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC206 in Children and Young Adults With DMG and Other CNS Tumors
NCT04732065Phase 1Recruiting
- Start
- Aug 2021
- Primary completion
- May 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label trial of ONC206 in diffuse midline glioma (DMG) and central nervous system tumor (4 arms). Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Maximum Tolerated Dose at 4 weeks. Started Aug 2021; status: recruiting.
02
Drugs
ONC206
03
Conditions
diffuse midline glioma (DMG)central nervous system tumor
Beyond the preview
Go deeper on NCT04732065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732065.